Our Assets

AngioSoma has a robust product pipeline, with patents, provisional patents, expired patents
with corporate intellectual property / knowledge, registered trademarks, and many more to come.
Here are the most important current corporate assets that contribute to our shareholder value.

LIPROSTIN™ PHARMACEUTICAL

Liprostin™ is a treatment for PAD that has completed FDA Phase I and three Phase II clinical trials. We are in discussions with contract research organizations (“CRO”) for completion of our U.S. Food and Drug Administration (“FDA”) protocol for Phase III and submission of our new drug application for marketing in the US and its territories.

TRANSDERMAL PGE-1 PATCH

The Transdermal PGE-1 Patch for the delivery of PGE-1 and / or Liprostin™ through the skin for the treatment of cardiovascular diseases is part of a group of 2 Provisional US Patents and 2 Non-Provisional US Patents filed in September 2016 by AngioSoma, Inc.

OMNICATH I & OMNICATH II

The OmniCath I is an atherectomy catheter that helps plaque removal by drilling, pulverizing and shaving it. The OmniCath I is protected by US Patent 5,728,129, and AngioSoma, Inc. is filing new patents currently which will, in conjunction with the original base patent, create the OmniCath™ II.

Soma Nutriceuticals, Inc. provides patented nutraceutical products that increase muscle mass as well as non-patented nutraceutical products with proprietary formulas for aiding sleep, erections, stamina, and other uses.

Our Team

AngioSoma’s team of professionals underscores the talent that has gone into
our pipeline of products as well as the ability to bring those products to value for our shareholders.
ALEXANDERIA BLANKENSHIP
CEO & President

Ms. Blakenship has overseen the acquisition of intellectual property consisting of multiple patents from a private corporation.

DAVID P. SUMMERS, PHD
Chairman Emeritus

‘Doc’ Summers is our Chairman Emeritus and provides over 35 years of research and development of the products within our product pipeline. Officer and founder of numerous public companies, he’s our “secret sauce”.

ROBERT L. SONFIELD, JR. ESQ
Corporate Counsel

Robert Leon Sonfield, Jr. esq is one of the founders of AngioSoma, Inc. as well as its corporate counsel. With over 55 years of practice of law, Mr. Sonfield has been part of hundreds of transactions as well as SEC reporting for hundreds of public companies.

A. TOMAS GARCIA. III, MD
Scientific Board of Advisors

Dr. Garcia is a practicing physician in the field of cardiology for the past 35 years and the immediate past president of the Texas Medical Association.

JACKIE R. SEE MD, FACC
Scientific Board of Advisors

Dr. See is a cardiologist and the principal inventor and author of the patent corporate of microsphere technology “PGE1-EDT”

PRESS RELEASES

As a publicly traded company, AngioSoma, Inc. provides news on its operations through press release distributors
like Business Wire, but it provides the same news here in an expanded format with links to all of the initial released
locations and expanded images. This conforms to Regulation FD disclosure requirements.

OUR SUBSIDIARIES

AngioSoma Research, Inc. (Texas)

This was the subsidiary with all the intellectual property (“IP”) that was purchased in June 2016 which was a precursor to First Titan Inc. renaming itself to AngioSoma, Inc.

SOMA Nutraceuticals, Inc. (Texas)

This is the subsidiary with all the IP purchased in November 2016 for nutraceutical development, marketing, and development.

AngioSoma Research, Inc. (Texas)

This was the subsidiary with all the intellectual property (“IP”) that was purchased in June 2016 which was a precursor to First Titan Inc. renaming itself to AngioSoma, Inc.

SOMA Nutraceuticals, Inc. (Texas)

This is the subsidiary with all the IP purchased in November 2016 for nutraceutical development, marketing, and development.

Contact Us

Address
2500 Wilcrest Dr, Houston, TX 77042
Phone
+1-832-781-8521
Email
investors@angiosoma.info